The 1969 Proceedings of the Plenary Session of the European Organization for Research on Treatment of Cancer have been divided between two volumes of a com pletely different nature. Volume 29, Aseptic Environments and Cancer Treatment, deals not only with the treatment of all types of cancer but also with aplastic treatment of bone marrow and certain other pathological conditions, such as immunological insufficiency, bums etc. Hence the volume will be of interest not only to carcinologists and haematologists but also to paediatricians, surgical units, intensive-care units, hospital administrators and architects and engineers who specialize in hospital design and equipment. Volume 30, Advances in the Treatment of Acute (Blastic) Leukemias, deals with a particular form of cancer and will have a more restricted readership of carcinologists specializing in leukemia and all haematologists. Paris, April 1970 GEORGES MATHE Contents Introduction. G. MATHE. 1 Five Years Experience of the Clinical Use of a Pathogen-Free Isolation Unit. G. MATHE, M. SCHNEIDER, 1. SCHWARZENBERG, J. 1. AMIEL, A. CATTAN, J. R. SCHLUMBERGER, M. HAYAT, F. DE VASSAL, CL. JASMIN, and CL. ROSEN- FELD. With 3 Figures . 3 Protected Environments and the Use of Antibiotics. H. E. M. KAY, J. BYRNE, B. JAMESON, and J. LYNCH . 14 Protected Environment, Prophylactic Antibiotics and Cancer Chemotherapy."

Tactics is the art of combining the action of troops or the proper means of different arms with the object of obtaining the maximum success at combat. Strategy is the art of combining the action of aB the military forces with a view to victory. This work, wh ich publishes the communications at the Annual General Meeting of the EORTC, wh ich was held in Paris in lune 1976, was devoted to tactics and to the therapeutic strategy with a view to the recovery of cancer patients. Table of Contents v Preface . I. Tactics G. MATHE: Tactics in Cancer Treatment: Introduction 1 1. Surgery F. ECONOMIDES and M. BRULEy-RosSET: Effects of the Removal of the Regional Lymph Nodes on the Survival of Mice Bearing B16 Melanoma or EAkR Lymphosarcoma . 2 U. VERONESI: Regional Lymph Node Dissection in Melanoma of the Limbs. Stage I-A Cooperative International Trial . 8 2. Chemotherapy G. MATHE, O. HALLE-PANNENKO, and C. BOURUT: Effectiveness of Murine Leukemia Chemotherapy According to the Immune State: Reconsideration of Correlations Between Chemotherapy, Tumour Cell Killing, and Survival Time 9 A. J. S. DAVIES: C "temotherapy of Tumours in Immuno-deprived Mice 13 P. POUILLART, G. MATHE, T. PALANGJE, J. LHERITIER, M. PmSSON, P. HUGUENIN, H. GAUTIER, P. MORIN, and R. PARROT: Treatment of Malignant Gliomas and Brain Metastases in Adults Using a Combination of Adriamycin, VM 26 and CCNU- Results of Type 11 Trial . 17 3. lmmunotherapy L. OLSSON: Immunologie and Cytokinetic Parameters of BCG-induced Growth Control of a Murine Leukemia .

The European Organization for Research into Cancer Treatment (OERTC), founded in 1962 initially under the name Groupe Europeen de Chimiotherapie Anti cancereuse (GECA), is an extramural European Institute for collecting, co-ordinating and encouraging the work of scientists researching into cancer treatment at 16 European institutes: 3 in W. Germany, 2 in Italy, 2 in Belgium, 3 in the Netherlands, 2 in the United Kingdom, 1 in Switzerland and 3 in France. The first President of OERTC was Professor GEORGES MATHE, now succeeded by Professor SILVIO GARATTINI of Milan. The organization has a Board of 20 Directors, responsible for co-ordinating the entire range of activities and guiding research and experimental studies on animals, also the first human trials of new therapeutic agents which have been fully tested on animals. The Co-operating Groups carry out com plementary testing involving large numbers of patients. Thus, OER TC is not a "learned society" but an agency for co-ordinating work. OER TC's annual plenary meeting for 1968 was held in Paris on 22nd and 23rd March. It was given over to an intensive study of the scientific basis of chemotherapy in the treatment of cancer in man. These two working sessions brought together members of all groups, both directing and co-operating. The first day was in effect a teaching seminar, open to all practitioners wishing to use chemotherapy in cancer, and explaining the scientific basis of such treatment. This seminar constitutes the present monograph."

Transplantation of syngeneic (donor is a monozygous twin) or allogeneic (donor is an HLA-identical sibling) marrow provides the opportunity for aggressive antileukemic therapy without regard to marrow toxicity. Until 1975, marrow transplantation was carried out only after failure of all other therapy. Consequently, most patients were in advanced relapse. Six of 16 recipients of syngeneic marrow and 13 of 100 recipients of allogeneic marrow are still in remission after 5. 5-10 years [3, 7]. An actuarial survival curve of the first 100 patients grafted in Seattle after conditioning with cyclophos phamide (60 mg/kg on each of 2 successive days) and total body irradiation (1,000 rad) showed three periods of interest: (1) The first 4 months showed a rapid loss of patients associated with advanced illness, graft-versus-host disease, infections (in particular interstitial pneumonias), and recurrent leukemia; (2) from 4 months to 2 years, the curve showed a much slower rate of decline attributable primarily to recurrent leukemia; and (3) from 2-10 years, the curve was almost flat with a negligible loss of patients and no recurrent leukemia. This flat portion of the curve corresponded to 13% of the patients and indicates a strong probability that the majority of these survivors are cured of their disease [8]. Attempts at reducing the incidence of leukemic relapse after transplantation were made by a number of marrow transplant groups by added chemotherapy.

The 1969 Proceedings of the Plenary Session of the European Organization for Research on Treatment of Cancer have been divided between two volumes of a com pletely different nature. Volume 29, Aseptic Environments and Cancer Treatment, deals not only with the treatment of all types of cancer but also with aplastic treatment of bone marrow and certain other pathological conditions, such as immunological insufficiency, bums etc. Hence the volume will be of interest not only to carcinologists and haematologists but also to paediatricians, surgical units, intensive-care units, hospital administrators and architects and engineers who specialize in hospital design and equipment. Volume 30, Advances in the Treatment of Acute (Blastic) Leukemias, deals with a particular form of cancer and will have a more restricted readership of carcinologists specializing in leukemia and all haematologists. Paris, April 1970 GEORGES MATHE Contents Introduction. G. MATHE. 1 Five Years Experience of the Clinical Use of a Pathogen-Free Isolation Unit. G. MATHE, M. SCHNEIDER, 1. SCHWARZENBERG, J. 1. AMIEL, A. CATTAN, J. R. SCHLUMBERGER, M. HAYAT, F. DE VASSAL, CL. JASMIN, and CL. ROSEN- FELD. With 3 Figures . 3 Protected Environments and the Use of Antibiotics. H. E. M. KAY, J. BYRNE, B. JAMESON, and J. LYNCH . 14 Protected Environment, Prophylactic Antibiotics and Cancer Chemotherapy."